Trenbolone hexahydrobenzylcarbonate
| Clinical data | |
|---|---|
| Trade names | Parabolan, Hexabolan |
| Other names | Trenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate |
| Routes of administration | Intramuscular |
| Drug class | Androgen; Anabolic steroid; Androgen ester; Progestogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.041.503 |
| Chemical and physical data | |
| Formula | C26H34O4 |
| Molar mass | 410.554 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trenbolone hexahydrobenzylcarbonate, or trenbolone cyclohexylmethylcarbonate, sold under the brand names Parabolan and Hexabolan, is a synthetic, injected anabolic–androgenic steroid (AAS) of the nandrolone group and an androgen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate) ester of trenbolone – which was marketed in France for medical use in humans but has since been discontinued.[1]
It was marketed from 1971 to 1997 for cachexia, recovery from major surgery, burns and pressure ulcers, and certain forms of osteoporosis. The standard dose was one ampoule (76 mg of trenbolone hexahydrobenzylcarbonate, equivalent to 50 mg base trenbolone) per fifteen days for a month, then one ampoule per month for three months.[2][3] The drug acts as a long-lasting prodrug of trenbolone when administered via intramuscular injection.[1]
See also
[edit]References
[edit]- 1 2 William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 619–. ISBN 978-0-9828280-1-4.
- ↑ "PARABOLAN solution injectable (arrêt de commercialisation)". BIAM – Banque de Données Automatisée sur les Médicaments (in French). Archived from the original on 7 June 2003.
- ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3307–. ISBN 978-0-8155-1856-3.
Further reading
[edit]- Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.
External links
[edit]- Trenbolone Hexahydrobenzylcarbonate - William Llewellyn's Anabolic.org Archived 2016-04-07 at the Wayback Machine
| Progestogens (and progestins) |
| ||||
|---|---|---|---|---|---|
| Antiprogestogens |
| ||||
| |||||
| ARTooltip Androgen receptor |
| ||||||
|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||
| PRTooltip Progesterone receptor |
| ||||||
|---|---|---|---|---|---|---|---|
| mPRTooltip Membrane progesterone receptor (PAQRTooltip Progestin and adipoQ receptor) |
| ||||||
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information. |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by adding missing information. |
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- CS1 French-language sources (fr)
- Webarchive template wayback links
- All stub articles